BRD7 promotes EP300-mediated acetylation of TP53

Stable Identifier
R-HSA-5628871
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

BRD7 promotes EP300 (p300)-mediated acetylation of TP53 on lysine residue K382, which enhances binding of TP53 to its target promoters. Also, BRD7 induces EP300-mediated acetylation of histone 3 on lysine residue K10 (also labeled in literature as K9), creating the H3K9 active chromatin mark at CDKN1A and MDM2 promoters (Drost et al. 2010), and possibly other TP53 promoters co-regulated by BRD7, such as SERPINE1, TIGAR, TNFRSF10C and NDRG1.

Literature References
PubMed ID Title Journal Year
20228809 BRD7 is a candidate tumour suppressor gene required for p53 function

Drost, J, Mantovani, F, Tocco, F, Elkon, R, Comel, A, Holstege, H, Kerkhoven, R, Jonkers, J, Voorhoeve, PM, Agami, R, Del Sal, G

Nat. Cell Biol. 2010
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
acetyltransferase activity of BRD7:p-S15,S20-TP53:EP300 [nucleoplasm]
Physical Entity
Activity
Orthologous Events
Authored
Reviewed
Created